GILEAD SCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
GILEAD SCIENCES, INC. (GILD) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2019-02-26
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-09-30 was 4.00M shares, a 42.86% decline year-over-year.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2018 was 0.00 shares.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2016 was 4.00M shares, a 80.00% decline from fiscal 2015.
- GILEAD SCIENCES, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 20.00M shares, a 67.74% decline from fiscal 2014.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 1 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-02-26 | ||||||||
| 2017-12-31 | 0.00 shares 10-K · filed 2019-02-26 | ||||||||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | |||||||
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-07 | 0.00 shares 10-Q · filed 2017-08-07 | |||||||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-10 | ||||||||
| 2016-12-31 | 4.00M shares 10-K · filed 2019-02-26 | ||||||||
| 2016-09-30 | 4.00M shares 10-Q · filed 2017-11-07 | 5.00M shares 10-Q · filed 2017-11-07 | |||||||
| 2016-06-30 | 6.00M shares 10-Q · filed 2017-08-07 | 6.00M shares 10-Q · filed 2017-08-07 | |||||||
| 2016-03-31 | 6.00M shares 10-Q · filed 2017-05-10 | ||||||||
| 2015-12-31 | 20.00M shares 10-K · filed 2018-02-27 | ||||||||
| 2015-09-30 | 7.00M shares 10-Q · filed 2016-11-07 | 26.00M shares 10-Q · filed 2016-11-07 | |||||||
| 2015-06-30 | 31.00M shares 10-Q · filed 2016-08-05 | 35.00M shares 10-Q · filed 2016-08-05 | |||||||
| 2015-03-31 | 39.00M shares 10-Q · filed 2016-05-06 | ||||||||
| 2014-12-31 | 62.00M shares 10-K · filed 2017-02-27 | ||||||||
| 2014-09-30 | 64.00M shares 10-Q · filed 2015-11-04 | 63.73M shares 10-Q · filed 2014-11-05 | 68.00M shares 10-Q · filed 2015-11-04 | 68.11M shares 10-Q · filed 2014-11-05 | |||||
| 2014-06-30 | 69.00M shares 10-Q · filed 2015-08-05 | 69.04M shares 10-Q · filed 2014-08-04 | 69.00M shares 10-Q · filed 2015-08-05 | 69.19M shares 10-Q · filed 2014-08-04 | |||||
| 2014-03-31 | 69.00M shares 10-Q · filed 2015-05-08 | 69.35M shares 10-Q · filed 2014-05-07 | |||||||
| 2013-12-31 | 63.00M shares 10-K · filed 2016-02-24 | 63.26M shares 10-K · filed 2014-02-25 | |||||||
| 2013-09-30 | 63.01M shares 10-Q · filed 2014-11-05 | 60.42M shares 10-Q · filed 2014-11-05 | |||||||
| 2013-06-30 | 65.05M shares 10-Q · filed 2014-08-04 | 56.65M shares 10-Q · filed 2014-08-04 | |||||||
| 2013-03-31 | 45.48M shares 10-Q · filed 2014-05-07 | ||||||||
| 2012-12-31 | 2.00M shares 10-K · filed 2015-02-25 | 1.58M shares 10-K · filed 2013-02-27 | |||||||
| 2012-09-30 | 2.60M shares 10-Q · filed 2013-10-31 | 1.30M shares 10-Q · filed 2012-11-06 | 0.00 shares 10-Q · filed 2013-10-31 | ||||||
| 2012-06-30 | 0.00 shares 10-Q · filed 2013-08-01 | 0.00 shares 10-Q · filed 2013-08-01 | |||||||
| 2011-12-31 | 0.00 shares 10-K · filed 2014-02-25 | ||||||||
| 2011-09-30 | 0.00 shares 10-Q · filed 2013-05-08 | 0.00 shares 10-Q · filed 2012-11-06 | |||||||
| 2010-12-31 | 0.00 shares 10-K · filed 2013-02-27 | ||||||||
| 2010-07-31 | 55.30M shares 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |